Skip to content
Curevo VaccineCurevo Vaccine
  • About
    • About Us
    • Management Team
  • Programs
    • Amezosvatein for Shingles
    • Amezosvatein for Chickenpox
  • Contact Us

Tag: varicella zoster virus

Phase 2 Enrollment of CRV-101 Completed
15 Sep, 2022
Press Releases

Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles

by curevovaccine
4 Comments
Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines 658x324
10 Feb, 2022
News, Press Releases, Vaccines

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

by curevovaccine

Recent Posts

  • Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention May 26, 2026
  • Curevo Enrolls First Participants in Phase 2 Extension Trial June 2, 2025
  • Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine March 17, 2025
  • Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine January 12, 2025

Categories

  • Events2
  • News8
  • Press Releases16
  • Vaccines8

Tags

  • adjuvanted vaccine
  • biotechnology company
  • clinical studies
  • CMO
  • CRV-101
  • Guy De La Rosa
  • infectious disease
  • investigational vaccine
  • JMP24
  • Scientific research
  • SHINGLES
  • Shingles Vaccine
  • Shingrix
  • subunit vaccines
  • VACCINE
  • varicella zoster virus
Curevo Vaccine logo white 158x90

___________________

A wholly owned subsidiary of Eli Lilly and Company

Curevo Inc.
18911 N Creek Pkwy #150
Bothell, WA 98011

+1.206.492.5722

Terms of Use
Privacy Policy
Cookie Policy

Consumer Health Privacy Notice

 © 2026 Curevo Inc.® All rights reserved.

Loading Comments...